RETROPHIN, INC. (NASDAQ:RTRX) Files An 8-K Costs Associated with Exit or Disposal Activities
ITEM 2.05 COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES
operations to its corporate headquarters in San Diego, CA. As
part of this plan, select employees will relocate from Cambridge,
MA to the San Diego headquarters by the end of 2017 and
replacements for other functions will be hired during the course
of 2017. The Company intends to close its Cambridge, MA office by
the end of 2017. This action is being taken as part of a
strategic effort to centralize expertise and improve efficiency,
with the goal of expediting the development of the Companys
late-stage clinical and early stage research programs. The
Company estimates it could incur up to $4.5 million in employee
related separation and transitional cash charges as a result of
this consolidation.
not historical facts are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements include, but are not limited to, statements
regarding the expected timelines to complete the planned
consolidation of operations; the anticipated costs associated
therewith; and the objective to centralize expertise and improve
efficiency, including the Companys goal of expediting the
development of the Companys late-stage clinical and early stage
research programs. Because such statements are subject to risks
and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon the Companys
current expectations and involve assumptions that may never
materialize or may prove to be incorrect. Actual results and the
timing of events could differ materially from those anticipated
in such forward-looking statements as a result of various risks
and uncertainties, including, without limitation, risks and
uncertainties associated with possible changes in the planned
consolidation and the timing of employee separations, relocations
and hirings, including as a result of changes that may occur in
the Companys operations or operating plan, or other reasons or
events. Related and other risks and uncertainties are described
more fully in the Companys filings with the Securities and
Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the year ended December 31, 2016. All
forward-looking statements contained in this report speak only as
of the date on which they were made. The Company undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
About RETROPHIN, INC. (NASDAQ:RTRX)
Retrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1. RETROPHIN, INC. (NASDAQ:RTRX) Recent Trading Information
RETROPHIN, INC. (NASDAQ:RTRX) closed its last trading session down -0.70 at 19.42 with 536,195 shares trading hands.